The FTSE 100 hit an all time high this week, and could reach 9,000 points by the end of 2025 according to the investment ...

Against a backdrop of rising U.S.-China geopolitical tensions, there are signs of growing dealmaking activity between Western ...

AstraZeneca's Calquence (acalabrutinib) has been approved by the U.S. FDA for the first-line treatment of adult patients with previously untreate ...

The U.S. Food and Drug Administration approved AstraZeneca (AZN, AZN.L) and Daiichi Sankyo's (DSKYF.PK) Datroway (datopotamab ...

If you suffered substantial losses and wish to serve as lead plaintiff of the AstraZeneca class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or ...

AstraZeneca said the U.S. Food and Drug Administration approved Datroway, a treatment for metastatic breast cancer developed in combination with Daiichi Sankyo.

Relay Therapeutics (market cap: $748.2 million), a biotechnology company focused on developing innovative cancer therapies, ...

DATROWAY Approved in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer ...

DXd, has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor HR-positive, HER2-negative breast cancer who have received prior endocrine-based ...

AstraZeneca restructures its China operations following leadership scandals and sales challenges, appointing new executives ...

Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against AstraZeneca PLC ("AstraZeneca" or the "Company") ...

AstraZeneca's Calquence gains FDA approval for untreated mantle cell lymphoma, supported by data showing improved survival and reduced disease progression.